
Delanzomib

Cat. No.:	HY-10454			
CAS No.:	847499-27-8			
Molecular Formula:	C ₂₁ H ₂₈ BN ₃ O ₅			
Molecular Weight:	413			
Target:	Proteasome; NF-κB; Apoptosis			
Pathway:	Metabolic Enzyme/Protease; NF-кВ; Apoptosis			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

SOLVENT & SOLUBILITY

DMSO : 100 mg/mL (2	42.13 mM; Need ultrasonic)					
	Solvent Mass Concentration	1 mg	5 mg	10 mg		
Preparing Stock Solutions	1 mM	2.4213 mL	12.1065 mL	24.2131 mL		
	5 mM	0.4843 mL	2.4213 mL	4.8426 mL		
	10 mM	0.2421 mL	1.2107 mL	2.4213 mL		
Please refer to the so	lubility information to select the ap	propriate solvent.				
1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (5.25 mM); Clear solution						
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.17 mg/mL (5.25 mM); Suspended solution; Need ultrasonic						
		rn oil				
	Preparing Stock Solutions Please refer to the so 1. Add each solvent Solubility: ≥ 2.17 r 2. Add each solvent Solubility: 2.17 mg 3. Add each solvent	Solvent Concentration 1 mM Stock Solutions 5 mM 10 mM Please refer to the solubility information to select the ap 1. Add each solvent one by one: 10% DMSO >> 40% PE Solubility: ≥ 2.17 mg/mL (5.25 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20 Solubility: 2.17 mg/mL (5.25 mM); Suspended solution	Solvent Mass Preparing 1 mM Stock Solutions 1 mM 2.4213 mL Stock Solutions 5 mM 0.4843 mL 10 mM 0.2421 mL Please refer to the solubility information to select the appropriate solvent. 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 Solubility: ≥ 2.17 mg/mL (5.25 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.17 mg/mL (5.25 mM); Suspended solution; Need ultrasonic 3. Add each solvent one by one: 10% DMSO >> 90% corn oil	Solvent Mass 1 mg 5 mg Preparing Stock Solutions 1 mM 2.4213 mL 12.1065 mL 5 mM 0.4843 mL 2.4213 mL 10 mM 0.2421 mL 1.2107 mL Please refer to the solubility information to select the appropriate solvent. 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (5.25 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.17 mg/mL (5.25 mM); Suspended solution; Need ultrasonic 3. Add each solvent one by one: 10% DMSO >> 90% corn oil		

BIOLOGICAL ACTIVIT	
BIOEOGICAL ACTIVIT	
Description	Delanzomib (CEP-18770) is a potent and orally active chymotrypsin-like activity of the proteasome inhibitor with an IC ₅₀ of 3.8 nM. Delanzomib inhibits NF-κB activity, induces cancer cell apoptotic, and has strong antiangiogenic and anti-cancer activities ^[1] .
IC ₅₀ & Target	IC50: 3.8 nM (Chymotrypsin-like activity of the proteasome) ^[1]
In Vitro	Delanzomib (CEP-18770; 20 nM; 12-24 hours) treatment results in a progressive appearance of cleaved caspases-3, -7, and -9



|| 0

ОН



between 12 and 24 hours' exposure in the human MM cell lines, RPMI-8226, and U266^[1]. Delanzomib (CEP-18770; 5-40 nM; 4-24 hours) treatment induces an accumulation of ubiquitinated proteins over 4 to 8 hours [1] Delanzomib (CEP-18770) inhibits endothelial cell survival, vasculogenesis, and osteoclastogenesis in vitro; and displays a favorable cytotoxicity profile toward normal cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis Analysis^[1] Cell Line: RPMI-8226, U266, and K562 cells Concentration: 20 nM Incubation Time: 12 hours, 24 hours Result: Resulted in a progressive appearance of cleaved caspases-3, -7, and -9 between 12 and 24 hours'exposure in the human MM cell lines. Western Blot Analysis^[1] Cell Line: RPMI-8226, U266, and K562 cells Concentration: 5 nM, 10 nM, 20 nM, 40 nM Incubation Time: 4 hours, 8 hours, 12 hours, 24 hours Result: Induced an accumulation of ubiquitinated proteins over 4 to 8 hours. Delanzomib (CEP-18770; 7.8-13 mg/kg; oral administration; twice a week; for 4 weeks) treatment results in a more sustained pharmacodynamic inhibition of proteasome activity in tumors relative to normal tissues, complete tumor regression of multiple myeloma (MM) xenografts and improves overall median survival in a systemic model of human MM^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SCID mice injected with RPMI 8226 cells^[1] Dosage: 7.8 mg/kg, 10 mg/kg, 13 mg/kg Administration: Oral administration; twice a week; for 4 weeks Result: Resulted in a more sustained pharmacodynamic inhibition of proteasome activity in tumors relative to normal tissues.

CUSTOMER VALIDATION

• Biol Pharm Bull. 2023;46(2):279-285.

See more customer validations on www.MedChemExpress.com

REFERENCES

In Vivo

[1]. Piva R, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008 Mar 1;111(5):2765-75.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA